WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (OTCBB: ACUS) today announced that an original paper summarizing the Phase 3 clinical trial results for ImagifyTM (Perflubutane Polymer Microspheres) for Injectable Suspension, a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States, has been published in the current issue of the European Journal of Echocardiography. The paper concludes that Imagify Perfusion Stress Echo is well-tolerated, and that its diagnostic performance in chest pain patients is comparable with single photo emission computed tomography, or SPECT, perfusion imaging. The paper, entitled “Detection of Coronary Artery Disease with Perfusion Stress Echocardiography Using a Novel Ultrasound Imaging Agent: Two Phase 3 International Trials in Comparison with Radionuclide Perfusion Imaging,” is authored by Dr. Roxy Senior, Consultant Cardiologist and Director of Cardiac Research, Department of Cardiovascular Medicine and Institute of Postgraduate Medical Education and Research at Northwick Park Hospital in the U.K., among others. Dr. Senior was the lead clinical investigator for Acusphere’s clinical trials for Imagify.
